Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, NSW, Australia; School of Medicine, Sydney Medical School, The University of Sydney, NSW, Australia.
Westmead Biobank, The Westmead Institute for Medical Research, NSW, Australia.
Int J Infect Dis. 2020 Apr;93:252-257. doi: 10.1016/j.ijid.2020.02.005. Epub 2020 Feb 13.
Evaluate the role of porins in the susceptibility of Klebsiella pneumoniae to ceftaroline and ceftaroline-avibactam.
Susceptibility to ceftaroline and ceftaroline-avibactam was tested by broth microdilution method in Klebsiella pneumoniae isolates (n = 65), including isogenic mutants (n = 30) and clinical isolates (n = 35), with different outer membrane porin defects in the presence or absence of beta lactamases.
Ceftaroline exhibited excellent activity against all the isogenic porin mutants with a MIC range of 0.125-0.25 μg/ml. Ceftaroline showed limited activity in the presence of extended spectrum β-lactamase enzymes in isogenic mutant constructs as expected but regained effectiveness in combination with avibactam against these isolates except those carrying metallo-carbapenemase (IMP-4) with an MIC range of 0.25->32 μg/ml. Ceftaroline-avibactam was able to inhibit 86% of the clinical isolates (n = 35) of Klebsiella pneumoniae carrying porin defects and multiple beta lactamases with only four isolates showing raised MICs against the combination (MIC range 0.125-4 μg/ml). One clinical isolate with IMP-4 carbapenemase had an MIC value of >32 μg/ml.
Outer membrane porins play a key role in the transport of ceftaroline inKlebsiella pneumoniae but it remains effective in isolates with altered permeability due to common porin mutations. The addition of avibactam substantially enhances the potency of ceftaroline providing an effective remedy to the problem of omnipresent beta lactamases in these bacteria.
评估孔蛋白在肺炎克雷伯菌对头孢洛林和头孢洛林-阿维巴坦敏感性中的作用。
采用肉汤微量稀释法检测 65 株肺炎克雷伯菌分离株(包括 30 株同源突变株和 35 株临床分离株)对头孢洛林和头孢洛林-阿维巴坦的敏感性,这些分离株在外膜孔蛋白缺陷不同(存在或不存在β-内酰胺酶)的情况下。
头孢洛林对所有同源孔蛋白突变株均表现出优异的活性,MIC 范围为 0.125-0.25μg/ml。在同源突变株构建体中存在扩展谱β-内酰胺酶时,头孢洛林的活性有限,这是预期的,但与阿维巴坦联合使用时,对这些分离株(除携带金属碳青霉烯酶(IMP-4)的分离株外)恢复了有效性,MIC 范围为 0.25->32μg/ml。头孢洛林-阿维巴坦能够抑制携带孔蛋白缺陷和多种β-内酰胺酶的 86%(n=35)肺炎克雷伯菌临床分离株,只有 4 株分离株对联合用药表现出升高的 MIC(MIC 范围为 0.125-4μg/ml)。一株携带 IMP-4 碳青霉烯酶的临床分离株的 MIC 值>32μg/ml。
外膜孔蛋白在肺炎克雷伯菌中头孢洛林的转运中起关键作用,但由于常见的孔蛋白突变导致通透性改变,它仍然有效。阿维巴坦的加入大大增强了头孢洛林的效力,为解决这些细菌中普遍存在的β-内酰胺酶问题提供了有效的治疗方法。